Medtronic Spine and Kyphon: The Reimbursement Advice Behind Inpatient Kyphoplasty Claims

Medtronic Spine agreed to pay $75 million in the Kyphon kyphoplasty settlement over allegations that its predecessor sold hospitals on unnecessary inpatient billing. The sales pitch allegedly came with a financial model showing hospitals how much they could make, provided they treated every kyphoplasty as an inpatient procedure. A device sale came with a plan for Medicare’s money.

What Kyphon Allegedly Sold With the Procedure

Kyphoplasty is a minimally invasive procedure for compression fractures of the spine, including fractures caused by osteoporosis, cancer or benign lesions. The Justice Department alleged that Kyphon’s seven-year marketing scheme steered certain hospitals toward more expensive inpatient admissions when outpatient treatment was clinically appropriate.

In the agreement announced on May 22, 2008, Medtronic Spine, which had taken over Kyphon, settled allegations that Kyphon’s counseling led hospitals to submit false inpatient kyphoplasty claims. That is the distinctive feature of this hospital billing fraud case. The company selling the device could influence the claim even though the hospital sent the bill.

How Reimbursement Advice Became Inpatient Claims

Device reimbursement managers and sales representatives allegedly supplied hospital inpatient billing instructions through a repeatable sales program. The complaint describes financial projections, physician screening and coding advice, all aimed at making the inpatient claim pay.

An inpatient stay receives a payment tied to its diagnosis-related group, with diagnoses and procedures affecting the classification. That gives the allegations their financial logic. The admission decision gets the case into the inpatient payment system. The documented conditions and procedures help determine what it pays.

The Profit Model Assumed Every Patient Would Be Admitted

According to the whistleblowers’ hospital complaint, Kyphon sales representatives and reimbursement managers began using a Hospital Economic Support Model in August 2003. It projected what hospitals could make from kyphoplasty on the assumption that all procedures would be inpatient. The classification was built into the sales model before an individual patient’s need for admission entered the picture.

The amended complaint against Kyphon put the price of a procedure kit at approximately $3,400 and a kit for a second vertebral level at approximately $2,300. The reimbursement model allegedly supplied the other side of the pitch: what Medicare would pay the hospital for using them.

The amended complaint put the sales instruction itself plainly:

The hospital complaint also alleged that physician training depended on willingness to use inpatient classification:

The physician also had to meet the regional sales manager, who allegedly checked that commitment. Training in the procedure came with a screening question about how it would be billed.

More Diagnoses and a Biopsy Could Raise the Payment

The complaint alleged that sales staff encouraged documentation of as many comorbidities as possible to support higher-paying DRG 233 even when the patient’s condition did not justify it. That puts the diagnosis coding alongside the admission decision: the alleged sales advice reached both.

The biopsy instruction was more direct:

The complaint alleged that adding a bone biopsy could increase the inpatient payment by up to $6,000, depending on geography. If the biopsy helped a hospital improperly classify a one-day case as inpatient rather than outpatient, the alleged additional reimbursement could reach $9,500. The amended complaint also alleged that representatives were trained to tell doctors that up to 4% of biopsies would uncover previously undiagnosed cancer.

A Return Visit Meant Another Full Payment

The hospital complaint alleged that doctors treating more than two vertebral levels were encouraged to bring patients back for a separate procedure. The hospital could then bill another full DRG payment. The whistleblowers alleged that these split visits also forced Medicare patients to pay unnecessary additional copayments. The payment strategy reached the patient’s wallet as well as the government’s.

The Manufacturer and Hospital Settlements Were Separate

The manufacturer case began with two former Kyphon employees who brought a qui tam case in Buffalo, New York. The Justice Department announced that the two whistleblowers would receive $14.9 million together from the manufacturer’s settlement. Kyphon also entered a corporate integrity agreement with the Department of Health and Human Services Office of Inspector General, requiring measures for future Medicare compliance.

The later hospital settlements addressed the claims from the other end: hospitals allegedly billing inpatient care to increase Medicare payments.

The December 2015 announcement added 32 hospitals paying more than $28 million, with approximately $4.75 million for the whistleblowers. By then, kyphoplasty inpatient billing settlements covered more than 130 hospitals and approximately $105 million, separate from the manufacturer payment.

The last group included the Cleveland Clinic and hospitals affiliated with Community Health Systems and Banner Health. One vendor’s reimbursement advice had become a national hospital billing investigation.

The admission pattern also appeared in Banner’s separate 2018 settlement for over $18 million. The government alleged that Banner billed short-stay procedures as inpatient care when they should have been outpatient and inflated reported observation hours.

What a Device or Hospital Insider Can See

A former Kyphon regional sales manager and a former reimbursement manager were the whistleblowers identified in the hospital kyphoplasty releases. Their jobs put them on the side that developed and delivered the billing advice. An employee inside the vendor could see a sales program that reached multiple hospital customers.

That perspective adds something a billing trend cannot explain on its own. RAND Corporation’s 2024 report, Methodologies to Measure Upcoding in Provider Settings, reviewed 39 articles and found that most examined coding patterns across hospitals or geographic areas rather than identifying individual upcoded admissions; just three tested coding against a gold standard, and the rest measured upcoding only indirectly.

The Kyphon allegations show what an insider’s account can add: the financial model, the training questionnaire and the instruction connecting a sales pitch to a hospital claim.

If you worked in device sales, reimbursement or hospital billing, those are recognizable parts of the business. The question is how the advice reached the claim, and who inside the organization understood the connection. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know How the Advice Reached the Bill

If you gave hospitals reimbursement advice or saw your hospital turn that advice into inpatient claims, speak to one of our whistleblower experts about what you saw. We connect the sales program to the Medicare claims and bring in whistleblower lawyers who know device marketing and hospital billing. We stay beside you from that first account through the case, building the strongest case your evidence supports.